Galapagos reported EUR-105748000 in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
argenx SE USD 245.36M 75.89M Jun/2025
AstraZeneca USD 2.45B 466M Jun/2025
Biogen USD 634.8M 394.3M Jun/2025
Genmab DKK 336M 141M Jun/2025
Gilead Sciences USD 1.96B 645M Jun/2025
GlaxoSmithKline GBP 1.44B 181M Jun/2025
GRIFOLS EUR 117.06M 57.34M Jun/2025
Hikma Pharmaceutical USD 133M 93M Dec/2024
Incyte USD 405M 246.8M Jun/2025
Merck EUR 652M 83M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Novartis USD 4.02B 418M Jun/2025
Roche Holding CHF 1.01B 2.12B Dec/2024
Sanofi EUR 3.94B 2.07B Jun/2025
UCB EUR 857M 649M Dec/2024
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025